KR20230061395A - O-당단백질-2-아세트아미도-2-데옥시-3-d-글루코피라노시다제 억제제의 결정질 형태 - Google Patents

O-당단백질-2-아세트아미도-2-데옥시-3-d-글루코피라노시다제 억제제의 결정질 형태 Download PDF

Info

Publication number
KR20230061395A
KR20230061395A KR1020237007569A KR20237007569A KR20230061395A KR 20230061395 A KR20230061395 A KR 20230061395A KR 1020237007569 A KR1020237007569 A KR 1020237007569A KR 20237007569 A KR20237007569 A KR 20237007569A KR 20230061395 A KR20230061395 A KR 20230061395A
Authority
KR
South Korea
Prior art keywords
crystalline
compound
powder diffraction
anhydrous
ray powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237007569A
Other languages
English (en)
Korean (ko)
Inventor
아스메롬 웰뎁
태 킴 코레이아
에어리얼 다이앤 젠킨스
이칭 린
샤오민 리
Original Assignee
바이오젠 엠에이 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이오젠 엠에이 인코포레이티드 filed Critical 바이오젠 엠에이 인코포레이티드
Publication of KR20230061395A publication Critical patent/KR20230061395A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
KR1020237007569A 2020-08-03 2021-08-03 O-당단백질-2-아세트아미도-2-데옥시-3-d-글루코피라노시다제 억제제의 결정질 형태 Pending KR20230061395A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063060281P 2020-08-03 2020-08-03
US63/060,281 2020-08-03
PCT/US2021/044341 WO2022031701A1 (en) 2020-08-03 2021-08-03 Crystaline forms of an o-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitor

Publications (1)

Publication Number Publication Date
KR20230061395A true KR20230061395A (ko) 2023-05-08

Family

ID=77640732

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237007569A Pending KR20230061395A (ko) 2020-08-03 2021-08-03 O-당단백질-2-아세트아미도-2-데옥시-3-d-글루코피라노시다제 억제제의 결정질 형태

Country Status (18)

Country Link
US (1) US20230286972A1 (https=)
EP (1) EP4188925A1 (https=)
JP (1) JP7789056B2 (https=)
KR (1) KR20230061395A (https=)
CN (1) CN116917284A (https=)
AR (1) AR123132A1 (https=)
AU (1) AU2021322186A1 (https=)
BR (1) BR112023002013A2 (https=)
CA (1) CA3188250A1 (https=)
CL (1) CL2023000327A1 (https=)
CO (1) CO2023002543A2 (https=)
CR (1) CR20230118A (https=)
IL (1) IL300365A (https=)
MX (1) MX2023001469A (https=)
PE (1) PE20231168A1 (https=)
TW (1) TW202220984A (https=)
UY (1) UY39366A (https=)
WO (1) WO2022031701A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2602139B (en) * 2020-12-18 2024-07-24 Nexeon Ltd Electroactive materials for metal-ion batteries
WO2025184490A1 (en) 2024-03-01 2025-09-04 Biogen Ma Inc. N-[4-fluor-5-[[(2s, 4 r)-4-[(6-methoxy-4-pyrimidinyl)oxy]- 2-methyl-1-pyrrolidinyl] methyl ]-2-thiazolyl]acetamid for use in the treatment of alzheimer disease

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2780014A4 (en) 2011-11-18 2015-07-01 Constellation Pharmaceuticals Inc MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF
US9051269B2 (en) 2011-11-18 2015-06-09 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
WO2013078320A1 (en) 2011-11-21 2013-05-30 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
JP5989805B2 (ja) 2012-02-10 2016-09-07 コンステレーション・ファーマシューティカルズ・インコーポレイテッドＣｏｎｓｔｅｌｌａｔｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． メチル基変更酵素の調節物質、組成物及びその使用
MA38341B1 (fr) 2013-02-11 2018-11-30 Constellation Pharmaceuticals Inc Modulateurs d'enzymes de modification par méthylation, compositions et utilisations associées
US9745305B2 (en) 2013-03-15 2017-08-29 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
US9969716B2 (en) 2013-08-15 2018-05-15 Constellation Pharmaceuticals, Inc. Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
EP3555087A1 (en) 2016-12-16 2019-10-23 Janssen Pharmaceutica NV Monocyclic oga inhibitor compounds
TWI654978B (zh) 2017-01-27 2019-04-01 美商美國禮來大藥廠 5－甲基－1,2,4－二唑－3－基化合物
WO2018154133A1 (en) 2017-02-27 2018-08-30 Janssen Pharmaceutica Nv [1,2,4]-triazolo [1,5-a]-pyrimidinyl derivatives substituted with piperidine, morpholine or piperazine as oga inhibitors
US12180205B2 (en) * 2018-09-19 2024-12-31 Biogen Ma Inc. O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors

Also Published As

Publication number Publication date
TW202220984A (zh) 2022-06-01
CN116917284A (zh) 2023-10-20
PE20231168A1 (es) 2023-07-26
US20230286972A1 (en) 2023-09-14
AU2021322186A1 (en) 2023-04-06
BR112023002013A2 (pt) 2023-05-02
MX2023001469A (es) 2023-06-16
EP4188925A1 (en) 2023-06-07
CR20230118A (es) 2023-06-02
CA3188250A1 (en) 2022-02-10
CO2023002543A2 (es) 2023-06-09
JP7789056B2 (ja) 2025-12-19
UY39366A (es) 2022-02-25
CL2023000327A1 (es) 2023-10-06
JP2023536911A (ja) 2023-08-30
IL300365A (en) 2023-04-01
WO2022031701A1 (en) 2022-02-10
AR123132A1 (es) 2022-11-02
WO2022031701A9 (en) 2022-03-31

Similar Documents

Publication Publication Date Title
US10081625B2 (en) 5-methyl-1,2,4-oxadiazol-3-yl compounds
EP3630755B1 (en) 5-methyl-1,3,4-oxadiazol-2-yl compounds
EP1912973B1 (en) Crystalline forms of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
TWI599358B (zh) 組合療法
KR20230145313A (ko) Bcl의 결정성 고체 메글루민 염 억제제 및 이의 제조 방법 및 이의 사용 방법
JP7789056B2 (ja) Ｏ－糖タンパク質－２－アセトアミド－２－デオキシ－３－ｄ－グルコピラノシダーゼ阻害剤の結晶形態
US20250313564A1 (en) Acidic salt or crystal form of nitrogen-containing fused ring derivative inhibitor, and preparation method therefor and use thereof
AU2017331930A1 (en) Crystalline forms
JP2024535860A (ja) Ｇｐｒ５２モジュレーター化合物
EA049044B1 (ru) Кристаллические формы ингибитора о-гликопротеин-2-ацетамидо-2-дезокси-3-d-глюкопиранозидазы
EP3829716B1 (en) 5-methyl-4-fluoro-thiazol-2-yl compounds
HK40111611B (zh) 含氮并环类衍生物抑制剂的酸式盐或晶型及其制备方法和应用
HK40111611A (zh) 含氮并环类衍生物抑制剂的酸式盐或晶型及其制备方法和应用
NZ754849B2 (en) N-[4-fluoro-5-[[(2s,4s)-2-methyl-4-[(5-methyl-1,2,4-oxadiazol-3-yl)methoxy]-1-piperidyl]methyl]thiazol-2-yl]acetamide as oga inhibitor
HK40009770B (en) N-[4-fluoro-5-[[(2s,4s)-2-methyl-4-[(5-methyl-1,2,4-oxadiazol-3-yl)methoxy]-1-piperidyl]methyl]thiazol-2-yl]acetamide as oga inhibitor
HK40009770A (en) N-[4-fluoro-5-[[(2s,4s)-2-methyl-4-[(5-methyl-1,2,4-oxadiazol-3-yl)methoxy]-1-piperidyl]methyl]thiazol-2-yl]acetamide as oga inhibitor

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902